Can MDCO Make Alnylam’s PCSK9 Candidate Work In The Hospital?
Executive Summary
Lagging the antibodies in the PCSK9 race, MDCO’s candidate brings certain strengths, not the least being a fundamentally different mechanism. But where the big boys will target larger populations in multiple settings, MDCO is hunkering down in the channel it knows best – the hospital cath lab – counting on changing practice behavior to speed its uptake.
You may also be interested in...
PCSK9 Battleground Hits The Court, Not The Market, After Amgen Sues
A month after filing a BLA for its cholesterol-lowering PCSK9 inhibitor, Amgen sues partners Sanofi and Regeneron claiming infringement of three patents that describe monoclonal antibodies to PCSK9.
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends
In shifting away from specific targets and non-statin add-on therapies, new ACC/AHA cholesterol guidelines support treatment of people at relatively low risk for events and more intensive therapy for those at higher risk.
The Medicines Co. Enters PCSK9 Race With Alnylam Deal
The Medicines Company and RNAi therapeutics company Alnylam have teamed up to develop a new drug targeting PCSK9 for the treatment of high cholesterol, but they are far behind the leaders in the pack and will have to differentiate their product from the others in the race.